Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Glioblastoma × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Triple Negative Breast Neoplasms 9 Neoplasms 7 Prostatic Neoplasms 6 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Leukemia, Myeloid, Acute 4 Fallopian Tube Neoplasms 4 Endometrial Neoplasms 4 Small Cell Lung Carcinoma 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrence 1 Prostate Cancer Metastatic 1 Primary Myelofibrosis 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Polycythemia Vera 1 Pathologic Complete Response 1 Osteosarcoma 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

Temozolomide 244 Radiotherapy 112 Bevacizumab 94 Magnetic Resonance Spectroscopy 50 Radiation 43 pembrolizumab 29 Irinotecan 27 Lomustine 20 Surgical Procedures, Operative 18 Radiosurgery 18 Nivolumab 17 Carmustine 16 Specimen Handling 15 Erlotinib Hydrochloride 15 Aminolevulinic Acid 15 Radiotherapy, Intensity-Modulated 13 Drug Therapy 12 Chemotherapy, Adjuvant 12 Carboplatin 12 Blood Specimen Collection 12 O(6)-benzylguanine 11 Cyclophosphamide 11 sargramostim 10 Thalidomide 10 Filgrastim 9 Etoposide 9 poly ICLC 8 Sunitinib 8 Imatinib Mesylate 8 Everolimus 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04740190 2025-06-11

TAC-GReD

The University of Hong Kong

Phase 2 Completed

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡